Current Problems in Pediatric and Adolescent Health Care
Volume 36, Issue 3 , Pages 97-103 , March 2006

Emerging Therapies in Juvenile Rheumatoid/Idiopathic Arthritis

  • Murray Passo, MD

      Affiliations

    • Corresponding Author InformationAddress reprint requests to Murray Passo, MD, Division of Rheumatology, Children’s Hospital, 3333 Burnet Ave., PAV 2-129, Cincinnati, OH 45229-3039.

References 

  1. Petty RE , Southland TR , Manners P , Baum J , Glass DN , Goldenberg J , et al.   International League of Associations for Rheumatology Classification of Juvenile Idiopathic Arthritis (second revision, Edmonton, 2001) . J Rheumatol . 2004;31(2):390–392
  2. Levinson JE , Wallace CA . Dismantling the pyramid . J Rheumatol Suppl . 1992;33:6–10
  3. Giannini EH , Brewer EJ , Kuzmina N , Shaikov A , Maximov A , Vorontsov I , et al.  The Pediatric Rheumatology Collaborative Study Group and The Cooperative Children’s Study Group   Methotrexate in resistant juvenile rheumatoid arthritis. Results of the U.S.A.–U.S.S.R. double-blind, placebo-controlled trial . N Engl J Med . 1992;326(16):1043–1049
  4. Takken T, Van der Net J, Helders PJ. Methotrexate for treating juvenile idiopathic arthritis. Cochrane Database Syst Rev 2001(3):CD003129.
  5. Carrasco R , Smith JA , Lovell D . Biologic agents for the treatment of juvenile rheumatoid arthritis (current status) . Paediatr Drugs . 2004;6(3):137–146
  6. Wilkinson N , Jackson G , Gardner-Medwin J . Biologic therapies for juvenile arthritis . Arch Dis Child . 2003;88(3):186–191
  7. Giannini EH , Ruperto N , Ravelli A , et al.   Preliminary definition of improvement in juvenile arthritis . Arthritis Rheum . 1997;40(7):1202–1209
  8. Ramanan AV , Whitworth P , Baildam EM . Use of methotrexate in juvenile idiopathic arthritis . Arch Dis Child . 2003;88(3):197–200
  9. Silverman E , Spiegel L , Hawkins D , Petty R , Goldsmith D , Schanberg L , et al.   Long-term open-label preliminary study of the safety and efficacy of leflunomide in patients with polyarticular-course juvenile rheumatoid arthritis . Arthritis Rheum . 2005;52(2):554–562
  10. Silverman E , Mouy R , Spiegel L , Jung LK , Saurenmann RK , Lahdenne P , et al.   Leflunomide or methotrexate for juvenile rheumatoid arthritis . N Engl J Med . 2005;352(16):1655–1666
  11. Lovell DJ , Giannini EH , Reiff A , Cawkwell GD , Silverman ED , Nocton JJ , et al.  Pediatric Rheumatology Collaborative Study Group   Etanercept in children with polyarticular juvenile rheumatoid arthritis . N Engl J Med . 2000;342(11):763–769
  12. Lovell DJ , Giannini EH , Reiff A , Jones OY , Schneider R , Olson JC , et al.   Long-term efficacy and safety of etanercept in children with polyarticular-course juvenile rheumatoid arthritis (interim results from an ongoing multicenter, open-label, extended-treatment trial) . Arthritis Rheum . 2003;48(1):218–226
  13. Lovell RA , Reiff A , Jones OY , et al.   Long-term safety and efficacy experience with etanercept in children with polyarticular juvenile rheumatoid arthritis . Arthritis Rheum . 2004;50(9):S436
  14. Horneff G , Schmeling H , Biedermann T , Foeldvari I , Ganser G , Girschick HJ , et al.   The German etanercept registry for treatment of juvenile idiopathic arthritis . Ann Rheum Dis . 2004;63(12):1638–1644
  15. Giannini EH , Lovell DJ , Ilowite NT , et al.   Safety outcomes from a Phase IV Pediatric Registry (etanercept therapy in children and adolescents with juvenile rheumatoid arthritis) . Arthritis Rheum . 2004;50(9):S90–S91
  16. Lahdenne P , Vahasalo P , Honkanen V . Infliximab or etanercept in the treatment of children with refractory juvenile idiopathic arthritis (an open label study) . Ann Rheum Dis . 2003;62(3):245–247
  17. Lovell D , Ruperto N , Cuttica R , et al.   Comparison of safety, efficacy and pharmacokinetics for 3 and 6mg/kg infliximab plus methotrexate therapy in JRA patients . Arthritis Rheum . 2005;52(Suppl):S724
  18. Weinblatt ME , Keystone EC , Furst DE , Moreland LW , Weisman MH , Birbara CA , et al.   Adalimumab, a fully human anti-tumor necrosis factor alpha monoclonal antibody, for the treatment of rheumatoid arthritis in patients taking concomitant methotrexate (the ARMADA trial) . Arthritis Rheum . 2003;48(1):35–45
  19. Gerloni V , Pontikaki I , Gattinara M , Desiati F , Lupi E , Lurati A , et al.   Efficacy of repeated intravenous infusions of an anti-tumor necrosis factor alpha monoclonal antibody, infliximab, in persistently active, refractory juvenile idiopathic arthritis (results of an open-label prospective study) . Arthritis Rheum . 2005;52(2):548–553
  20. Lovell RN , Ruperto N , Goodman S , et al.   Preliminary data from the study of adlimumab in children with juvenile idiopathic arthritis . Arthritis Rheum . 2004;50(9):S436–S437
  21. Dinarello CA . Therapeutic strategies to reduce IL-1 activity in treating local and systemic inflammation . Curr Opin Pharmacol . 2004;4(4):378–385
  22. Brennan FM , Maini RN , Feldmann M . TNF alpha—a pivotal role in rheumatoid arthritis? . Br J Rheumatol . 1992;31(5):293–298
  23. Brennan FM , Chantry D , Jackson A , Maini R , Feldmann M . Inhibitory effect of TNF alpha antibodies on synovial cell interleukin-1 production in rheumatoid arthritis . Lancet . 1989;2(8657):244–247
  24. Fleischmann RMSJ , Bennett R , Handel ML , Burmester GR , Tesser J , Modafferi D , et al.   Anakinra, a recombinant human interleukin-1 receptor antagonist (r-metHuIL-1ra), in patients with rheumatoid arthritis (a large, international, multicenter, placebo-controlled trial) . Arthritis Rheum . 2003;48(4):927–934
  25. Jiang Y , Genant HK , Watt I , Cobby M , Bresnihan B , Aitchson R , et al.   A multicenter, double-blind, dose-ranging, randomized, placebo-controlled study of recombinant human interleukin-1 receptor antagonist in patients with rheumatoid arthritis (radiologic progression and correlation of Genant and Larsen scores) . Arthritis Rheum . 2000;43(5):1001–1009
  26. Nuki G , Bresnihan B , Bear MB , McCabe D  European Group of Clinical Investigators . Long-term safety and maintenance of clinical improvement following treatment with anakinra (recombinant human interleukin-1 receptor antagonist) in patients with rheumatoid arthritis (extension phase of a randomized, double-blind, placebo-controlled trial) . Arthritis Rheum . 2002;46(11):2838–2846
  27. Cohen S , Hurd E , Cush J , Schiff M , Weinblatt ME , Moreland LW , et al.   Treatment of rheumatoid arthritis with anakinra, a recombinant human interleukin-1 receptor antagonist, in combination with methotrexate (results of a twenty-four-week, multicenter, randomized, double-blind, placebo-controlled trial) . Arthritis Rheum . 2002;46(3):614–624
  28. Irigoyen P , Olson J , Hom C , et al.   Treatment of systemic onset juvenile rheumatoid arthritis with anakinra . Arthritis Rheum . 2004;50(1):S437–S438
  29. Henrickson M . Efficacy of anakinra in refractory systemic arthritis . Arthritis Rheum . 2004;50(9):S438
  30. Pascual V , Allantaz F , Arce E , Punaro M , Banchereau J . Role of interleukin-1 (IL-1) in the pathogenesis of systemic onset juvenile idiopathic arthritis and clinical response to IL-1 blockade . J Exp Med . 2005;201(9):1479–1486
  31. Economides AN , Carpenter LR , Rudge JS , Wong V , Koehler-Stec EM , Hartnett C , et al.   Cytokine traps (multi-component, high-affinity blockers of cytokine action) . Nat Med . 2003;9(1):47–52
  32. Dinarello CA . Setting the cytokine trap for autoimmunity . Nat Med . 2003;9(1):20–22
  33. De Benedetti F , Martini A . Is systemic juvenile rheumatoid arthritis an interleukin 6 mediated disease? . J Rheumatol . 1998;25(2):203–207
  34. de Benedetti F , Martini A . Targeting the interleukin-6 receptor (a new treatment for systemic juvenile idiopathic arthritis?) . Arthritis Rheum . 2005;52(3):687–693
  35. Nishimoto N , Kishimoto T . Inhibition of IL-6 for the treatment of inflammatory diseases . Curr Opin Pharmacol . 2004;4(4):386–391
  36. Yokota S , Miyamae T , Imagawa T , Iwata N , Katakura S , Mori M , et al.   Therapeutic efficacy of humanized recombinant anti-interleukin-6 receptor antibody in children with systemic-onset juvenile idiopathic arthritis . Arthritis Rheum . 2005;52(3):818–825
  37. Yokota S , Imagawa T , Miyamae T , et al.   Long-term therapeutic experience of humanized anti-IL-6 receptor monoclonal antibody (aIL-6R Mab) in systemic-onset juvenile idiopathic arthritis (So-JIA) . Arthritis Rheum . 2004;50(9):S438
  38. Kremer JM , Dougados M , Emery P , Durez P , Sibilia J , Shergy W , et al.   Treatment of rheumatoid arthritis with the selective costimulation modulator abatacept (twelve-month results of a phase iib, double-blind, randomized, placebo-controlled trial) . Arthritis Rheum . 2005;52(8):2263–2271
  39. Cron RQ . A signal achievement in the treatment of arthritis . Arthritis Rheum . 2005;52(8):2229–2232
  40. Kremer JM , Westhovens R , Leon M , DiGiorgio E , Alten R , Steinfeld S , et al.   Treatment of rheumatoid arthritis by selective inhibition of T-cell activation with fusion protein CTLA4Ig . N Engl J Med . 2003;349(20):1907–1915

PII: S1538-5442(05)00131-8

doi: 10.1016/j.cppeds.2005.10.011

Current Problems in Pediatric and Adolescent Health Care
Volume 36, Issue 3 , Pages 97-103 , March 2006

Article Tools